ESSENTIAL VIEWING: KEY TRIALS FROM SABCS® 2025

ED4-02

Beyond hot flashes: Addressing unmet needs in menopause care after breast cancer

Commentary by: Maryam Lustberg, MD, MPH

ED4-04

The Winding Road of MHT: Evidence, Messaging, and an Evidence Informed Approach to Discussing MHT with Women at Elevated Risk 

Commentary by: Lisa Larkin, MD, FACP, MSCP, IF

ED4-05

Rethinking menopause and breast cancer: is it time to change practice?

Commentary by: Maryam Lustberg, MD, MPH

RF2-01

Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) – a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials

Commentary by: Joseph Sparano, MD, FACP

RF2-02

Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer

Commentary by: Joseph Sparano, MD, FACP

RF2-03

Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial

Commentary by: Joseph Sparano, MD, FACP

RF2-04

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high-risk early-stage triple-negative breast cancer (CITRINE): a phase 3 randomized trial

Commentary by: Joseph Sparano, MD, FACP

RF2-06

Impact of Immune Checkpoint Inhibition (CPI) on Fertility in Young Women with Early Triple-Negative Breast Cancer (TNBC) receiving neoadjuvant Chemotherapy (NACT): A Prospective Substudy of the NSABP B-59/GBG-96-GeparDouze Trial

Commentary by: Joseph Sparano, MD, FACP

RF2-07

Nodal disease burden in patients with clinically node-positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting: pre-planned TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Commentary by: Joseph Sparano, MD, FACP

GS1-01

Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer

Commentary by: Matteo Lambertini, MD, PhD

GS1-03

Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: an exploratory analysis from the ALTTO (BIG 2-06) trial

Commentary by: Matteo Lambertini, MD, PhD

GS1-04

Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN-1181/CompassHER2 pCR trial 

Commentary by: Matteo Lambertini, MD, PhD

GS1-05

Prognostic and predictive associations of manual, digital and AI-derived tumor infiltrating lymphocytes-scoring: A retrospective analysis from the Phase III APHINITY trial

Commentary by: Matteo Lambertini, MD, PhD

GS1-06

Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study 

Commentary by: Kevin Kalinsky, MD, MS, FASCO

GS1-08

Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx

Commentary by: Joseph Sparano, MD, FACP

GS1-09

Sacituzumab Govitecan vs. Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07

Commentary by: Kevin Kalinsky, MD, MS, FASCO

GS1-10

Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial

Commentary by: Hope S. Rugo, MD

GS1-10 (Spanish Version)

Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial

Commentary by: Agatha Reyes, MD

GS1-11

lidERA and Advent of Adjuvant SERDs

Commentary by: Hope S. Rugo, MD

GS1-01 (Japanese Version)

Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer

Commentary by: Prof Eriko Tokunaga

GS1-04 (Japanese Version)

Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN-1181/CompassHER2 pCR trial 

Commentary by: Prof Eriko Tokunaga

GS1-06 (Japanese Version)

Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): Translational analysis of PHERGain neoadjuvant tailored treatment study 

Commentary by: Prof. Shigehira Saji

GS1-08 (Japanese Version)

Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx

Commentary by: Prof. Shigehira Saji

GS1-09 (Japanese Version)

Sacituzumab Govitecan vs. Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07

Commentary by: Prof. Shigehira Saji

GS1-10 (Japanese Version)

Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial

Commentary by: Prof. Shigehira Saji

RF6-01

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05

Commentary By: Giuseppe Curigliano, MD, PhD

RF6-02

DESTINY-Breast11 (DB-11) safety: neoadjuvant trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

Commentary By: Giuseppe Curigliano, MD, PhD

RF6-03

Efficacy and safety of DP303c versus T-DM1 in HER2-positive advanced breast cancer: Interim analysis of a randomized, open-label, phase 3 trial​

Commentary By: Giuseppe Curigliano, MD, PhD

RF6-06

Patient-reported outcomes (PROs) in DESTINY-Breast11: neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

Commentary By: Giuseppe Curigliano, MD, PhD

RF6-07

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study

Commentary By: Giuseppe Curigliano, MD, PhD

ED6-01

Moving on up: ADCs in early-stage breast cancer

Commentary by: Kevin Kalinsky, MD, MS, FASCO

RF3-02

Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial

Commentary by: Peter Fasching, MD

RF3-04

Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial

Commentary by: Peter Fasching, MD

RF3-07

A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer 

Commentary by: Peter Fasching, MD

GS2-01

More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy – primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R)study

Commentary by Sheldon Feldman, MD, FACS

GS2-02

Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial

Commentary by: Sheldon Feldman, MD

GS2-03

Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial

Commentary by: Sheldon Feldman, MD

GS2-05

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

Commentary by Sheldon Feldman, MD, FACS

GS2-07

Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694

Commentary by Sheldon Feldman, MD, FACS

GS2-09

The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505)

Commentary by Sheldon Feldman, MD, FACS

RF7-01

Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study

Commentary by: Hope S. Rugo, MD

RF7-02

Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor (EPIK-B5): Phase III, randomized, double-blind, placebo-controlled, multicenter study

Commentary by: Adam Brufsky, MD, PhD

RF7-03

Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

Commentary by: Adam Brufsky, MD, PhD

RF7-04

Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial

Commentary by: Adam Brufsky, MD, PhD

RF7-05

Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial

Commentary by: Adam Brufsky, MD, PhD

RF7-06

Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden

Commentary by: Adam Brufsky, MD, PhD

RF7-07

Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival

Commentary by: Adam Brufsky, MD, PhD

SS8-01A

New Drug Approvals for HR+ Metastatic Breast Cancer: Antibody Drug Conjugates - (Dato-DXd) & (T-DXd) - Part 1

Commentary By: Ruth O'Regan, MD

SS8-01B

New Drug Approvals for HR+ Metastatic Breast Cancer: Antibody Drug Conjugates - (Dato-DXd) & (T-DXd) - Part 2

Commentary By: Ruth O'Regan, MD

SS8-02

New Drug Approvals for HR+ Metastatic Breast: Imlunestrant (INLURIYO)

Commentary By: Ruth O'Regan, MD

PS4-11-26 (Spanish Version)

First latin american consensus on the medical oncology management of early-stage hr+/her2− breast cancer: addressing regional disparities in spanish-speaking countries of central and south america

Commentary By: Denis Ulises Landaverse, MD

RF4-01

Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)

Commentary By: Sarah Sammons, MD

RF4-02

Efficacy Analysis of the Randomized Phase III DETECT V trial: Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer

Commentary By: Sarah Sammons, MD

RF4-03

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05

Commentary By: Sarah Sammons, MD

GS3-05

Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial

Commentary By: Hope S. Rugo, MD

GS3-07

Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0

Commentary By: Hope S. Rugo, MD

GS3-08

Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Updated efficacy results from the phase 3 EMBER-3 trial

Commentary By: Hope S. Rugo, MD

GS3-09

Clinical and biomarker subgroup analysis of evERA Breast Cancer: A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor

Commentary By: Hope S. Rugo, MD

RF5-02

Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts

Commentary By:
William Gradishar, MD, FASCO, FACP

RF5-02 (Spanish Version)

Tbcrc 056: a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohorts

Commentary by: Fernando Petracci, MD, MSc, PhD

RF5-03 (Spanish Version)

OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with brca mutations and early-stage her2-negative breast cancer

Commentary by: Fernando Petracci, MD, MSc, PhD

RF5-05

Predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations according to their homologous recombination status by the RAD51 test: Primary analysis of the RADIOLA phase II trial

Commentary By:
William Gradishar, MD, FASCO, FACP

RF5-06

Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial

Commentary By:
William Gradishar, MD, FASCO, FACP

SS5-03

Year In Review - Early Breast Cancer

William Gradishar, MD

SS5-04

Year In Review - Metastatic Breast Cancer

Commentary By:
Janice Tsang, MBBS, MRCP, FRCP, FHKCP